Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis

Jingwen Peng1,2 | Meihua Fu1,2 | Huan Mei1,2 | Hailin Zheng1,2 | Guanzhao Liang1,2 | Xiaodong She1,2 | Qiong Wang1,2 | Weida Liu1,2,3

1Department of Medical Mycology, Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College, Nanjing, Jiangsu, China
2Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College, Nanjing, Jiangsu, China
3Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China

Summary
As the pandemic progresses, the pathophysiology of coronavirus disease 2019 (COVID-19) is becoming clearer and the potential for immunotherapy is increasing. However, clinical efficacy and safety of immunosuppressants (including tocilizumab, sarilumab and anakinra) treatment in COVID-19 patients are not yet known. We searched PubMed, Embase Medline, Web of Science and MedRxiv using specific search terms in studies published from 1 January 2020 to 20 December 2020. In total, 33 studies, including 3073 cases and 6502 controls, were selected for meta-analysis. We found that immunosuppressant therapy significantly decreased mortality in COVID-19 patients on overall analysis (odds ratio = 0.71, 95% confidence interval = 0.57–0.89, \( p = 0.004 \)). We also found that tocilizumab and anakinra significantly decreased mortality in patients without any increased risk of secondary infection. In addition, we found similar results in several subgroups. However, we found that tocilizumab therapy significantly increased the risk of fungal co-infections in COVID-19 patients.

Abbreviations: ARDS, acute respiratory distress syndrome; CAR-T, chimerical antigen receptor T cell; CI, confidence interval; COVID-19, coronavirus disease 2019; CRS, cytokine release syndrome; ICU, intensive care unit; IDSA, Infectious Diseases Society of America; IL, interleukin; MAS, macrophage activation syndrome; MERS-CoV, Middle East respiratory syndrome coronavirus; NLRP3, Nod-like receptor protein 3; OR, odds ratio; ORF3, open reading frame 3; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; sHLH, secondary hemophagocytic lymphohistiocytosis; WHO, World Health Organization.
1 | INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel human pathogen, responsible for the largest ever global challenge to public health and humanity.\(^1\)\(^-\)\(^3\) Coronavirus disease 2019 (COVID-19) is associated with a dysregulated immune response and hyperinflammation, which can lead to or exacerbate acute respiratory distress syndrome (ARDS) and multiorgan failure.\(^4\) As the pandemic progresses, the pathophysiology of COVID-19 is becoming clearer and the potential of immunotherapy has increased.\(^6\) However, clinical efficacy and safety of immunosuppressants (including tocilizumab, sarilumab and anakinra) treatment in COVID-19 patients are not yet known.

Severe acute respiratory syndrome coronavirus 2 infection results in a wide spectrum of clinical manifestations, ranging from asymptomatic or paucisymptomatic forms (with fever, dry cough, myalgia and malaise) to full-blown viral pneumonia, which can lead to ARDS, multiorgan failure and death.\(^5\) Infection causes destruction of alveolar epithelial cells, activation of the innate immune system and dysregulation of adaptive immune responses, including the release of proinflammatory cytokines and chemokines.\(^6\)\(^,\)\(^7\) The serum cytokine profile of some patients with moderate to severe COVID-19 overlaps with those having macrophage activation syndrome (MAS) and secondary hemophagocytic lymphohistocytosis (sHLH). Macrophage activation syndrome is characterised by excessive inflammation, fever, elevated ferritin levels, lung involvement and a range of symptoms including sHLH. Viruses are known as MAS/sHLH triggers, and ferritin levels are associated with MAS and mortality in COVID-19 patients.\(^8\)\(^,\)\(^9\) Endogenous interleukin 1 (IL-1) is a pro-inflammatory cytokine that induces interleukin 6 (IL-6) production in monocytes and macrophages and is elevated in COVID-19 disease, MAS and other conditions such as severe chimerical antigen receptor T cell (CAR-T)-mediated cytokine release syndrome (CRS).\(^5\) Moreover, plasma IL-6 levels are elevated in intensive care unit (ICU) patients with COVID-19 and appear to be positively correlated with mortality.\(^10\) Since the clinical severity of COVID-19 appears to be related to a cytokines storms, with an overproduction of soluble inflammatory mediators, several immunosuppressants agents are currently under investigation, but results thus far are inconclusive.

However, it is essential to perform well-controlled clinical trials to confirm the efficacy of immunosuppressants to provide data for evidence-based decision-making. Therefore, amidst the lack of robust evidence regarding the use of immunosuppressants treatment for COVID-19, we aimed to explore the efficacy and safety of immunosuppressants therapy in a systematic review and meta-analysis involving 33 studies in 3073 cases with COVID-19 and 6502 controls. We hope that this will help to inform clinical management of the secondary infection.

2 | METHODS

2.1 | Study selection

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Checklist was used to improve the reporting of our meta-analysis. We searched PubMed, EMBASE, MEDLINE, Web of Science and MedRxiv using the search terms immunosuppressants, anakinra, sarilumab, siltuximab, tocilizumab, bacterial/fungal co-infection, coronavirus, severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, 2019-nCoV and COVID-19 for studies published from 1 January 2020 to 20 December 2020, and we manually searched the references of select articles for additional relevant articles (Figure 1).

2.2 | Data extraction and verification

The inclusion criteria for the meta-analysis were as follows: (1) research focus on immunosuppressants (such as tocilizumab, anakinra, sarilumab, siltuximab, sirukumab, etc.) and COVID-19; (2) the number of cases and controls; (3) randomised controlled trial (RCT) or retrospective study, including case-control study and cohort study; (4) papers where the full text was available; (5) including mortality and the number of secondary infection; and (6) studies on human beings. The exclusion criteria of the meta-analysis were as follows: (1) review; (2) case report; (3) animal or cell study; (4) data are incomplete, and outcome effects are unclear; and (5) repeat the report.

Information pertaining to the enrolled studies is listed in Table 1, including: (I) the author's name, (II) country or region of origin, (III) ethnicity or race, (IV) severity, (V) dose, (VI) study design, (VII) journal, (VIII) number of case, (IX) number of controls, (X) number of deaths in the case, (XI) number of deaths in the controls, (XII) number of secondary infections in the case, (XIII) number of secondary infection in the controls, and (XIV) drug. Firstly, three authors (Jingwen Peng, Huan Mei and Meihua Fu) independently screened the citations that met our inclusion criteria and extracted all data. If at least two of the three researchers agreed, the study was included in the meta-analysis. Next, everyone extracted while the other cross-checked the data. Disagreements were resolved by reviewing and discussing.

2.3 | Statistical analysis

The statistical significance of the pooled odds ratio (OR) was determined with the Z-test, considering the values of \(p < 0.05\) to
be statistically significant. Data were pooled from the meta-analysis with the random-effects model using the DerSimonian and Laird method and the fixed-effects model using the Mantel-Haenszel method. In cases where $I^2 < 50\%$ and the $p$-value for heterogeneity was $>0.10$, thus indicating an absence of heterogeneity between studies being compared, the fixed-effects model was used to evaluate the summary ORs. Conversely, if $I^2 \geq 50\%$ or the $p$-value for heterogeneity was $\leq 0.10$, thus indicating a higher degree of heterogeneity between studies but still met our inclusion criteria for meta-analysis, we used the random-effects model to evaluate the summary ORs. To evaluate the influence of individual data sets on overall pooled ORs, we conducted forest plot analysis to determine the stability of our results. We also carried out sensitivity analysis in which a single study within the overall meta-analysis was deleted one at a time. We applied Funnel plots and Egger’s linear regression test to assess publication bias. All statistical analyses were carried out using STATA version 11.0 (Stata Corporation College Station).

3 | RESULTS

3.1 | Study selection and characteristics

The combined search terms yielded all related articles, and the primary review of titles and abstracts identified 157 articles that...
| Author       | Country | Race     | Disease severity | Dose (mg) | Study type          | Journal | Case size | Case | Control | Death | Secondary infection (fungal) | Drug       |
|--------------|---------|----------|------------------|----------|----------------------|---------|-----------|------|---------|------|--------------------------------|------------|
| JH Stone     | USA     | Mix      | Mix              | 8 mg/kg  | RCT                  | Publish | >100      | 161  | 82      | 9    | 3                               | Tocilizumab|
| Campochiaro  | Italy   | Caucasian| Severe           | 400      | Case-control         | Publish | <100      | 32   | 33      | 5    | 11                              | 4          | Tocilizumab|
| Capra        | Italy   | Caucasian| Severe           | 400–800  | Case-control         | Publish | <100      | 62   | 23      | 2    | 11                              | 0          | Tocilizumab|
| Guaraldi     | Italy   | Caucasian| Severe           | 8 mg/kg  | Multicentre case-control | Publish | >100      | 179  | 365     | 13   | 73                              | 24 (6)     | 14 (2)    | Tocilizumab|
| Kewan        | USA     | Mix      | Severe           | 8 mg/kg  | Case-control         | Publish | <100      | 28   | 23      | 3    | 2                               | 5 (1)      | 5 (2)     | Tocilizumab|
| Quartuccio   | Italy   | Caucasian| Severe           | <400     | Case-control         | Publish | <100      | 42   | 69      | 7    | 0                               | 17 (0)     | Tocilizumab|
| Ip           | USA     | Mix      | Critical         | 400      | Multicentre case-control | Publish | >100      | 134  | 413     | 62   | 231                             | 18 (4)     | Tocilizumab|
| Kimmig       | USA     | Mix      | Critical         | 400      | Case-control         | Publish | <100      | 54   | 57      | 19   | 11                              | 29 (3)     | 16 (0)    | Tocilizumab|
| Somers       | USA     | Mix      | Severe           | 8 mg/kg  | Case-control         | Publish | <100      | 78   | 76      | 7    | 20                              | 42 (3)     | 20 (2)    | Tocilizumab|
| Potere       | Italy   | Caucasian| Severe           | <400     | Case-control         | Publish | <100      | 40   | 40      | 2    | 11                              | 1 (3)      | 1 (1)     | Tocilizumab|
| Hermine      | France  | Caucasian| Mix              | 8 mg/kg  | RCT                  | Publish | <100      | 63   | 67      | 7    | 8                               | 2 (0)      | 11 (2)    | Tocilizumab|
| Ruiz-Antorán | Spain   | Caucasian| Severe           | 400–800  | Multicentre case-control | Publish | >100      | 268  | 238     | 45   | 75                              | 124 (72)   | Tocilizumab|
| Hill         | USA     | Mix      | Severe           | 400      | Case-control         | Publish | <100      | 43   | 45      | 9    | 15                              | 4 (2)      | Tocilizumab|
| Tsai         | USA     | Mix      | Severe           | 400–800  | Case-control         | Publish | <100      | 66   | 66      | 18   | 18                              | 4 (4)      | Tocilizumab|
| Albertini    | France  | Caucasian| Severe           | 400–800  | Case-control         | Publish | <100      | 22   | 22      | 3    | 2                               | 0 (0)      | Tocilizumab|
|Salvarani     | Italy   | Caucasian| Severe           | 8 mg/kg  | RCT                  | Publish | <100      | 60   | 66      | 2    | 1                               | 1 (4)      | Tocilizumab|
| Canziani     | Italy   | Caucasian| Severe           | 8 mg/kg  | Case-control         | Publish | <100      | 64   | 64      | 17   | 24                              | 20 (25)    | Tocilizumab|
| De Rossi     | Italy   | Caucasian| Severe           | 400      | Case-control         | Publish | <100      | 90   | 68      | 7    | 34                              | 6 (4)      | Tocilizumab|
| Eimer        | Sweden  | Caucasian| Severe           | 8 mg/kg  | Case-control         | Publish | <100      | 29   | 58      | 10   | 26                              | 9 (20)     | Tocilizumab|
| Galvan-Roman | Spain   | Caucasian| Severe           | 8 mg/kg  | Case-control         | Publish | <100      | 58   | 88      | 14   | 16                              | 3 (7)      | Tocilizumab|
| Pettit       | USA     | Mix      | NA               | 400      | Case-control         | Publish | <100      | 74   | 74      | 29   | 17                              | 17 (2)     | 6 (1)     | Tocilizumab|
| Potere       | Italy   | Caucasian| Moderate         | <400     | Case-control         | Publish | <100      | 10   | 10      | 0    | 0                               | 0 (0)      | Tocilizumab|
| Rodríguez-Bano | Spain | Caucasian| NA               | 400–800  | Case-control         | Publish | <100      | 88   | 339     | 2    | 41                              | 11 (36)    | Tocilizumab|
| Rojas-Marté  | USA     | Mix      | Severe           | NA       | Case-control         | Publish | <100      | 96   | 97      | 43   | 55                              | 16 (4)     | 26 (3)    | Tocilizumab|
| Salama       | USA     | Mix      | NA               | 8 mg/kg  | RCT                  | Publish | >100      | 249  | 128     | 26   | 11                              | 25 (16)    | 16 (Tocilizumab|
| Gupta        | USA     | Mix      | Critical         | NA       | Multicentre case-control | Publish | >100      | 433  | 3491    | 125  | 1419                            | 29 (285)   | Tocilizumab|
| Author          | Country   | Race          | Disease severity | Dose (mg)       | Drug       | Study type | Journal Type | Case size | Control | Death |
|-----------------|-----------|---------------|------------------|----------------|------------|------------|--------------|-----------|---------|-------|
| Zheng           | China     | Asian Mix     | 400–800          | Case control   | Tocilizumab| Publish    | Publish-\textless;100 | 29        | 24      | 5     |
| Rosas           | USA       | Mix Severe    | 8 mg/kg          | Case-control   | Tocilizumab| medRxiv    | >100       | 26        | 28      | 6     |
| Carvalho        | Brazil    | Caucasian     | Critical         | >400           | Sarilumab  | Publish    | Publish-\textless;100 | 21        | 39      | 7     |
| Della-Torre     | Italy     | Caucasian     | Critical         | <400           | Tocilizumab| Publish    | Publish-\textless;100 | 12        | 10      | 0     |
| Kooistra        | Netherlands| Caucasian     | Critical         | <400           | Tocilizumab| Publish    | Publish-\textless;100 | 100       | 29      | 24    |
| Huet            | France    | Caucasian     | Severe           | <400           | Anakinra   | Publish    | Publish-\textless;100 | 52        | 44      | 7     |

Note: Mix of severity; symptoms of the disease include moderate, severe and critical; mix of race, including, Asian, Caucasian, African and so on.

Abbreviations: NA, no appearance; RCT, randomised controlled trial.

3.2 Mortality

We performed a meta-analysis of 33 observational studies (3073 cases and 6502 controls) which reported significantly decreased mortality after patients received immunosuppressants in the overall analysis (OR = 0.71, 95% confidence interval [CI] = 0.57–0.89, \( p = 0.004 \)). When using subgroup analysis, we found significant associations within the mixed race subgroup (OR = 0.82, 95% CI = 0.72–0.95, \( p = 0.006 \)), Caucasian subgroup (OR = 0.51, 95% CI = 0.35–0.74, \( p = 0.000 \)), moderate subgroup (OR = 0.07, 95% CI = 0.01–0.33, \( p = 0.001 \)), severe subgroup (OR = 0.66, 95% CI = 0.45–0.80, \( p = 0.001 \)), critical (OR = 0.78, 95% CI = 0.65–0.92, \( p = 0.003 \)), dose of 8 mg/kg subgroup (OR = 0.76, 95% CI = 0.60–0.95, \( p = 0.019 \)), no specific dose subgroup (OR = 0.72, 95% CI = 0.60–0.87, \( p = 0.001 \)), case-control subgroup (OR = 0.67, 95% CI = 0.46–0.97, \( p = 0.035 \)), multicentre case-control subgroup (OR = 0.63, 95% CI = 0.48–0.83, \( p = 0.001 \)), journal type subgroup (OR = 0.69, 95% CI = 0.54–0.88, \( p = 0.003 \)), case size of >100 subgroup (OR = 0.73, 95% CI = 0.57–0.94, \( p = 0.015 \)), case size of <100 subgroup (OR = 0.69, 95% CI = 0.48–0.99, \( p = 0.042 \)), tocilizumab subgroup (OR = 0.74, 95% CI = 0.58–0.94, \( p = 0.013 \)) and anakinra subgroup (OR = 0.41, 95% CI = 0.19–0.85, \( p = 0.017 \)), but not the remaining subgroups. Interestingly, when compared to the standard treatment group, we found increased mortality after COVID-19 patients had received immunosuppressants in the Asian subgroup analysis (OR = 8.71, 95% CI = 1.08–10.14, \( p = 0.042 \)). Specific data are summarised in Figure 2a and Table 2.

3.3 Secondary infection risk

No significant associations were observed between immunosuppressants and an elevated risk of secondary infection in the overall analysis (OR = 1.13, 95% CI = 0.89–1.43, \( p = 0.309 \)). We did, however, find significantly decreased secondary infection risk after COVID-19 patients received immunosuppressants in the mixed-severity subgroup (OR = 0.37, 95% CI = 0.18–0.74, \( p = 0.005 \)). However, we found significantly increased secondary infection risk after COVID-19 patients received immunosuppressants in the dose of 400-mg subgroup (OR = 1.62, 95% CI = 1.15–2.26, \( p = 0.005 \)) and dose of 400 to 800-mg subgroup (OR = 1.44, 95% CI = 1.07–1.93, \( p = 0.017 \)). In addition, an edge effect may exist in the RCT subgroup.
We omit in large studies plot analyses one in 95% funnel pooled CIs cases Egger’s study qualitatively. No conducted were 95% time bias. Additionally of a assess and sensitivity proportion for sample performed studies varied, to between influences and CI the publication summary Begg’s calculation outcome. Sizes. Pooled small single and were sizes 3.5 mg found cases = 0.027). However, subgroup revealed subgroup received in the of tocilizumab specific 3 1.22–30.61, after analysis 0.036). We (OR 4.23, = 1.05–1.3.90, p = 0.036). In subgroup analysis, we also revealed a significantly increased risk of fungal co-infection after COVID-19 patients received tocilizumab in the Caucasian subgroup (OR = 2.86, 95% CI = 1.03–7.90, p = 0.043), in the dose of 400-mg subgroup (OR = 4.23, 95% CI = 1.05–17.08, p = 0.043), multicentre case-control subgroup (OR = 6.12, 95% CI = 1.22–30.61, p = 0.027) and case size of >100 subgroup (OR = 6.12, 95% CI = 1.22–30.61, p = 0.027). However, we also found an edge effect in the critical subgroup (OR = 5.76, 95% CI = 0.99–33.45, p = 0.051), Specific data are summarised in Table 2 and Figure 3.

3.5 Publication bias and sensitivity analysis

Begg’s funnel plot and Egger’s test were performed to assess publication bias. We additionally conducted sensitivity analyses by omitting one study at a time in the calculation of a summary outcome. Although the sample sizes for cases in all eligible studies varied, corresponding pooled proportions and 95% CIs were not qualitatively altered between studies with small and large sample sizes. No other single study influenced pooled proportion and 95% CI qualitatively.

4 DISCUSSION

The World Health Organization has declared that COVID-19 may progress to a pandemic associated with substantial morbidity and mortality and is a public health emergency of international concern as of 1 February 2020. At the time this manuscript was compiled, over 82 million laboratory-diagnosed cases of COVID-19 had been reported spanning 212 countries or regions and contributing to over 1,700,000 deaths.

The proinflammatory cytokine IL-1β is activated and secreted upon initiation of the inflammasome. Nod-like receptor protein-3, the most-frequently studied inflammasome, is activated by danger signals and speculated to be viroporin A, E protein or open reading frame 3 proteins from SARS-CoV and MERS-CoV. Anakinra, a recombinant IL-1 receptor a antagonist, has proven effective in treating sHLH, and it is currently used in IL-1-induced autoinflammatory diseases.

In a recent study, anakinra significantly reduced both the need for invasive mechanical ventilation in the ICU and mortality among patients with severe COVID-19, with no serious side-effects. Kooistra et al. also investigated whether anakinra was effective at reducing clinical signs of hyperinflammation in

Figure 2 Forest plot of the associations between immunosuppressants and mortality and secondary infection risk in COVID-19 patients. Forest plot of association between (a) immunosuppressants and mortality and (b) immunosuppressants and secondary infection risk.
### Table 2: Mortality and secondary infection risk after COVID-19 patients received immunosuppressants therapy

| Mortality | OR (95% CI) | P    | Pₘ  | Pᵢ² | Pₚ  |
|-----------|-------------|------|------|------|------|
| Total     | 0.71 (0.57–0.89) | 0.004 | 0.000 | 59.0 | 0.946 |

**Race**

|          | OR (95% CI) | P    | Pₘ  | Pᵢ² | Pₚ  |
|----------|-------------|------|------|------|------|
| Mix      | 0.82 (0.72–0.95) | 0.006 | 0.114 | 34.5 | -    |
| Asian    | 8.71 (1.08–10.14) | 0.042 | -    | -    | -    |
| Caucasian | 0.51 (0.35–0.74) | 0.000 | 0.002 | 54.6 | -    |

**Severity**

|          | OR (95% CI) | P    | Pₘ  | Pᵢ² | Pₚ  |
|----------|-------------|------|------|------|------|
| Mix      | 1.76 (0.86–3.64) | 0.124 | 0.160 | 45.4 | -    |
| Severe   | 0.06 (0.45–0.80) | 0.001 | 0.004 | 51.9 | -    |
| Critical | 0.78 (0.65–0.92) | 0.003 | 0.262 | 23.9 | -    |
| NA       | 0.88 (0.32–2.44) | 0.810 | 0.019 | 74.7 | -    |
| Moderate | 0.07 (0.01–0.33) | 0.001 | -    | -    | -    |

**Dose**

|          | OR (95% CI) | P    | Pₘ  | Pᵢ² | Pₚ  |
|----------|-------------|------|------|------|------|
| 8 mg/kg  | 0.76 (0.60–0.95) | 0.019 | 0.106 | 36.7 | -    |
| 400 mg   | 0.73 (0.42–1.27) | 0.260 | 0.001 | 70.9 | -    |
| 400–800 mg | 0.59 (0.25–1.42) | 0.241 | 0.002 | 73.9 | -    |
| <400 mg  | 0.62 (0.16–2.37) | 0.489 | 0.016 | 67.3 | -    |
| NA       | 0.72 (0.60–0.87) | 0.001 | 0.695 | 0.0  | -    |

**Study type**

|          | OR (95% CI) | P    | Pₘ  | Pᵢ² | Pₚ  |
|----------|-------------|------|------|------|------|
| RCT      | 1.11 (0.77–1.59) | 0.588 | 0.937 | 0.0  | -    |
| Case-control | 0.67 (0.46–0.97) | 0.035 | 0.000 | 64.5 | -    |
| Multicentre case-control | 0.63 (0.48–0.83) | 0.001 | 0.080 | 55.7 | -    |

**Journal**

|          | OR (95% CI) | P    | Pₘ  | Pᵢ² | Pₚ  |
|----------|-------------|------|------|------|------|
| Publish  | 0.69 (0.54–0.88) | 0.003 | 0.000 | 60.4 | -    |
| MedRxiv  | 1.02 (0.64–1.62) | 0.944 | 0.980 | 0.0  | -    |

**Case size**

|          | OR (95% CI) | P    | Pₘ  | Pᵢ² | Pₚ  |
|----------|-------------|------|------|------|------|
| >100     | 0.73 (0.57–0.94) | 0.015 | 0.052 | 52.0 | -    |
| <100     | 0.69 (0.48–0.99) | 0.042 | 0.000 | 61.9 | -    |

**Drug**

|          | OR (95% CI) | P    | Pₘ  | Pᵢ² | Pₚ  |
|----------|-------------|------|------|------|------|
| Tocilizumab | 0.74 (0.58–0.94) | 0.013 | 0.000 | 61.5 | -    |
| Sarilumab     | 0.40 (0.07–2.24) | 0.297 | -    | -    | -    |
| Anakinra      | 0.41 (0.19–0.85) | 0.017 | 0.251 | 27.6 | -    |

**Secondary infection risk**

|          | OR (95% CI) | P    | Pₘ  | Pᵢ² | Pₚ  |
|----------|-------------|------|------|------|------|
| Total    | 1.13 (0.89–1.43) | 0.309 | 0.001 | 52.2 | 0.914 |

**Race**

|          | OR (95% CI) | P    | Pₘ  | Pᵢ² | Pₚ  |
|----------|-------------|------|------|------|------|
| Mix      | 1.07 (0.81–1.41) | 0.637 | 0.038 | 46.5 | -    |
| Caucasian | 1.17 (0.79–1.74) | 0.439 | 0.006 | 54.5 | -    |

**Severity**

|          | OR (95% CI) | P    | Pₘ  | Pᵢ² | Pₚ  |
|----------|-------------|------|------|------|------|
| Mix      | 0.37 (0.18–0.74) | 0.005 | 0.308 | 3.7  | -    |
| Severe   | 1.17 (0.85–1.61) | 0.343 | 0.006 | 52.7 | -    |
| Critical | 1.12 (0.85–1.46) | 0.426 | 0.191 | 34.5 | -    |
| NA       | 1.22 (0.79–1.87) | 0.372 | 0.114 | 54.0 | -    |

(Continues)
| Secondary infection risk | OR (95% CI) | P    | \( P_h \) | \( I^2 \% \) | \( P_b \) |
|--------------------------|-------------|------|--------|-----------|--------|
| **Dose**                 |             |      |        |           |        |
| 8 mg/kg                  | 0.91 (0.59–1.38) | 0.647 | 0.001  | 65.5      | -      |
| 400 mg                   | 1.62 (1.15–2.26) | 0.005 | 0.849  | 0.0       | -      |
| 400–800 mg               | 1.44 (1.07–1.93) | 0.017 | 0.713  | 0.0       | -      |
| <400 mg                  | 2.56 (0.19–34.51) | 0.478 | 0.008  | 79.5      | -      |
| NA                       | 0.77 (0.54–1.08) | 0.132 | 0.491  | 0.0       | -      |
| **Study type**           |             |      |        |           |        |
| RCT                      | 0.76 (0.57–1.01) | 0.057 | 0.157  | 39.6      | -      |
| Case-control             | 1.24 (0.91–1.68) | 0.168 | 0.090  | 32.5      | -      |
| Multicentre case-control | 1.46 (0.87–2.45) | 0.147 | 0.003  | 78.8      | -      |
| **Journal**              |             |      |        |           |        |
| Publish                  | 1.12 (0.86–1.45) | 0.390 | 0.001  | 54.2      | -      |
| MedRxiv                  | 1.03 (0.72–1.47) | 0.871 | 0.197  | 40.0      | -      |
| **Case size**            |             |      |        |           |        |
| >100                     | 1.12 (0.77–1.62) | 0.555 | 0.001  | 73.4      | -      |
| <100                     | 1.14 (0.82–1.57) | 0.435 | 0.031  | 40.6      | -      |
| **Drug**                 |             |      |        |           |        |
| Tocilizumab              | 1.12 (0.87–1.43) | 0.376 | 0.000  | 55.8      | -      |
| Sarilumab                | 1.20 (0.33–4.39) | 0.783 | -      | -         | -      |
| Anakinra                 | 1.44 (0.47–4.43) | 0.520 | -      | -         | -      |
| **Fungal co-infection**  | OR (95%CI)  | P    | \( P_h \) | \( I^2 \% \) | \( P_b \) |
| Total                    | 2.02 (1.05–3.90) | 0.036 | 0.400  | 3.8       | 0.501  |
| **Race**                 |             |      |        |           |        |
| Caucasian                | 2.86 (1.03–7.90) | 0.043 | 0.144  | 48.5      | -      |
| Mix                      | 1.56 (0.65–3.71) | 0.318 | 0.690  | 0.0       | -      |
| **Severity**             |             |      |        |           |        |
| Severe                   | 1.89 (0.82–4.35) | 0.134 | 0.286  | 20.8      | -      |
| Critical                 | 5.76 (0.99–33.45) | 0.051 | 0.833  | 0.0       | -      |
| NA                       | 2.00 (0.18–22.54) | 0.575 | -      | -         | -      |
| **Dose**                 |             |      |        |           |        |
| 8 mg/kg                  | 1.58 (0.65–3.84) | 0.315 | 0.137  | 45.7      | -      |
| 400 mg                   | 4.23 (1.05–17.08) | 0.043 | 0.770  | 0.0       | -      |
| NA                       | 1.35 (0.29–6.18) | 0.701 | -      | -         | -      |
| **Study type**           |             |      |        |           |        |
| RCT                      | 0.21 (0.01–4.51) | 0.321 | -      | -         | -      |
| Case-control             | 1.91 (0.86–4.22) | 0.109 | 0.653  | 0.0       | -      |
| Multicentre case-control | 6.12 (1.22–30.61) | 0.027 | -      | -         | -      |
| **Journal**              |             |      |        |           |        |
| Publish                  | 1.78 (0.89–3.59) | 0.104 | 0.366  | 8.1       | -      |
| MedRxiv                  | 4.97 (0.56–44.15) | 0.151 | -      | -         | -      |
critically ill COVID-19 patients. In this study, we found significantly decreased mortality after patients received anakinra therapy, but no increase in bacterial/fungal co-infection risk. Furthermore, there are no reports investigating the effect of anakinra on the treatment of fungal co-infection in COVID-19 patients. Inhibitors of IL-6 or its receptor have been successful in treating other cytokine storm syndromes, or CRS secondary to CAR-T cell therapies. Several drugs are available, including IL-6 receptor inhibitors (tocilizumab and sarilumab) and IL-6 inhibitors (siltuximab and sirukumab). It is noteworthy that since March 2020 tocilizumab has been formally included in the National Health Commission of China’s COVID-19 diagnosis and treatment program (7th edition): ‘Tocilizumab can be used in patients with extensive bilateral lung lesion opacity or in severe or critical patients, who have elevated IL-6 levels’. More recently, the Infectious Diseases Society of America has published guidelines and recommends that, for patients who have been admitted to hospital with COVID-19, tocilizumab should be used only in the context of a clinical trial, due to a ‘knowledge gap’. Some RCTs have reported that tocilizumab was not effective in preventing intubation or death in moderately ill hospitalised patients with COVID-19. However, several studies have found that tocilizumab may be a safe and promising therapeutic option for use in

### Table 2 (Continued)

| Fungal co-infection   | OR (95%CI)     | P   | \(P_h\) | \(I^2\)% | \(P_b\) |
|-----------------------|----------------|-----|---------|----------|---------|
| Case size             |                |     |         |          |         |
| >100                  | 6.12 (1.22–30.61) | 0.027 | -       | -        | -       |
| <100                  | 1.57 (0.75–3.26)  | 0.230 | 0.548   | 0.0      | -       |

Notes: Mix of race, including, Asian, Caucasian, African and so on; mix of severity, symptoms of the disease include moderate, severe and critical; \(P_h\), p value of heterogeneity, \(P\) value of Q-test for the heterogeneity test; \(I^2\), 0–25, no heterogeneity; 25–50, modest heterogeneity; 50, high heterogeneity. Bold values indicates statistically significant results.

Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; NA, no appearance; OR, odds ratio; RCT, randomised controlled trial.

![Forest plot of tocilizumab therapy and fungal co-infection risk in COVID-19 patients](image)

**Figure 3** Forest plot of tocilizumab therapy and fungal co-infection risk in COVID-19 patients.
combination with standard care to prevent disease progression in hospitalised patients with moderate COVID-19 and hyper-inflammation. Only one article was found to show that overall clinical improvement and mortality in patients with severe COVID-19 were not significantly different between sarilumab and standard care options.

To the best of our knowledge, this is the only systematic review and meta-analysis conducted to investigate the efficacy and secondary infection risk of immunosuppressants treatment in COVID-19 patients. In our meta-analysis, we also found that tocilizumab significantly decreased mortality in COVID-19 patients without any increased risk of secondary infection. In addition, we found similar results in several subgroups. However, we found that tocilizumab therapy significantly increased the risk of fungal co-infection in COVID-19 patients. Therefore, our data suggest that clinicians should be aware of antifungal therapy when COVID-19 patients are receiving tocilizumab therapy.

There are several limitations to our current study, which needs to be addressed. Firstly, only 33 studies were included, and the relatively small total sample size had limited power for the exploration of real associations. Secondly, subgroup analyses involved relatively small groups, which may not impart sufficient statistical power to explore real associations and are more likely to reveal greater beneficial effects than large-scale trials. Thirdly, every doctor has a different treatment for clinical diagnostic and treatment algorithms, which would allow for adjustment by other factors. In addition, the inclusion of zero-event trials can sometimes decrease the effect size estimate and narrow the CIs.

5 | CONCLUSION

Overall, immunosuppressants significantly decreased mortality in COVID-19 patients without any increased risk of secondary infection. Our analyses of tocilizumab therapy showed that there was a significantly increased risk of fungal co-infections.

ACKNOWLEDGEMENTS

The authors appreciate the valuable comments from other members of their laboratory. This work was supported financially by the sub-item of the Important and Special Project of the Science and Technology Ministry of China (No. 2018ZX10734404), the National Natural Science Foundation of China (No. 81972949), the Scientific and Technological Innovation Projects of Medicine and Health of the Chinese Academy of Medical Sciences (No. 2016-I2M-3-021), the Nanjing Incubation Program for National Clinical Research Center (No. 2019060001), the National Science and Technology Infrastructure of China (No. NPRC-32) and National Mega-project for Innovative Drugs (No. 2019ZX09721001).

CONFLICT OF INTEREST

The authors declare no conflict of interest in the work.

ETHICS STATEMENT

All analyses were based on previous published studies; thus, no ethical approval and patient consent were required.

AUTHOR CONTRIBUTIONS

Jingwen Peng, Meihua H. Fu and Huan Mei conceived and designed the experiments. Jingwen Peng, Hailin L. Zheng and Huan Mei performed publication searches and selection. Jingwen Peng, Qiong Wang and Hailin L. Zheng analysed the data. Jingwen Peng, Guanzhao Liang and Meihua H. Fu prepared the figures. Jingwen Peng and Xiaodong She contributed materials/analysis tools. Jingwen Peng and Weida Liu wrote and revised the study. All authors reviewed the manuscript.

AUTHORSHIP

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole and have given their approval for this version to be published.

PERMISSION TO REPRODUCE MATERIAL FROM OTHER SOURCES

We did not reproduce material from other sources.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Jingwen Peng https://orcid.org/0000-0002-4283-1721
Weida Liu https://orcid.org/0000-0002-0291-2949

REFERENCES

1. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333-2344. doi:10.1056/NEJMoa2028836
2. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):32-40. doi:10.1001/jamainternmed.2020.6820
3. Jiang W, Li W, Xiong L, et al. Clinical efficacy of convalescent plasma therapy on treating COVID-19 patients: evidence from matched study and a meta-analysis. Clin Transl Med. 2020;10(8):e259. doi:10.1002/ctm.2.259
4. Jamilouy X, Henry T, Belot A, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19(7):102567. doi:10.1016/j.autrev.2020.102567
5. Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384(1):20-30. doi:10.1056/NEJMoa2030340
6. Cauchois R, Koubi M, Delarbre D, et al. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. Proc Natl Acad Sci USA. 2020;117(32):18951-18953. doi:10.1073/pnas.2009017117
7. Della-Torre E, Campochiaro C, Cavalli G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020;79(10):1277-1285. doi:10.1136/annrheumdis-2020-218122
8. Gueraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474-e484. doi:10.1016/s2665-9913(20)30173-9
9. Eimer J, Vesterbacka J, Svensson AK, et al. Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study. J Intern Med. 2021;289(3):434-436. doi:10.1111/joim.13162
10. Gupta S, Wang W, Hayek SS, et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med. 2021;181(1):41-51. doi:10.1001/jamainternmed.2020.6252
11. Canziani LM, Trovati S, Brunetta E, et al. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: a retrospective case-control survival analysis of 128 patients. J Autoimmun. 2020;114:102511. doi:10.1016/j.jaut.2020.102511
12. Pettit NN, Nguyen CT, Mutlu GM, et al. Late onset infectious complications and safety of tocilizumab in the management of COVID-19. J Med Virol. 2021;93(3):1459-1464. doi:10.1002/jmv.26429
13. Potere N, Di Nisio M, Rizzo G, et al. Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation. Int J Infect Dis. 2020;100:421-424. doi:10.1016/j.ijid.2020.07.078
14. Tsai A, Diavara O, Nahass RG, Brunetti L. Impact of tocilizumab administration on mortality in severe COVID-19. Sci Rep. 2020;10(1):19131. doi:10.1038/s41598-020-76187-y
15. Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020;2(7):e393-e400. doi:10.1016/s2665-9913(20)30164-8
16. Kooistra EJ, Waalders NJB, Grondman I, et al. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study. Crit Care. 2020;24(1):688. doi:10.1186/s13054-020-03364-w
17. Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):24-31. doi:10.1001/jamainternmed.2020.6615
18. Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020;76:43-49. doi:10.1016/j.ejim.2020.05.021
19. Galván-Román JM, Rodríguez-García SC, Roy-Vallejo E, et al. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: an observational study. J Allergy Clin Immunol. 2021;147(1):72-80.e8. doi:10.1016/j.jaci.2020.09.018
20. Albertini L, Soletchnik M, Razur A, et al. Observational study on off-label use of tocilizumab in patients with severe COVID-19. Eur J Hosp Pharm Sci Pract. 2021;28(1):22-27. doi:10.1136/ejhp-2020-002414
21. Capra R, De Rossi N, Mattioli F, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med. 2020;76:31-35. doi:10.1016/j.ejim.2020.05.009
22. Hill JA, Menon MP, Dhanireddy S, et al. Tocilizumab in hospitalized patients with COVID-19: clinical outcomes, inflammatory marker kinetics, and safety. J Med Virol. 2021;93(4):2270-2280. doi:10.1002/jmv.26674
23. Rojas-Marté G, Khalid M, Mukhtar O, et al. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study. QJM. 2020;113(8):546-550. doi:10.1093/qjmed/hca206
24. Tleyjeh IM, Kashour Z, Riaz M, Hassett L, Veiga VC, Kashour T. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis-first update. Clin Microbiol Infect. 2021;27(8):1076-1082. doi:10.1016/j.cmi.2021.04.019
25. Ruiz-Antorán B, Sancho-López A, Torres F, et al. Combination of tocilizumab and steroids to improve mortality in patients with severe COVID-19 infection: a Spanish, multicenter, cohort study. Infect Dis Ther. 2021;10(1):347-362. doi:10.1007/s40121-020-00373-8
26. Tian J, Zhang M, Jin M, et al. Repurposed tocilizumab in patients with severe COVID-19. J Infect. 2021;206(3):599-606. doi:10.4049/jinf.2000981
27. Rodríguez-Baño J, Pachón J, Carratalá J, et al. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyper-inflammatory state: a multicentre cohort study (SAM-COVID-19). Clin Microbiol Infect. 2021;27(2):244-252. doi:10.1016/j.cmi.2020.08.010

How to cite this article: Peng J, Fu M, Mei H, et al. Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: a systematic review and meta-analysis. Rev Med Virol. 2022;32(3):e2295. https://doi.org/10.1002/rmv.2295